HRMY•benzinga•
Harmony Biosciences Reports $714M 2024 Revenue For WAKIX; 2025 Forecast $820M-$860M With Potential $1B+; Key Catalysts In Each Quarter; FDA Review For Pitolisant sNDA, Orexin Data, Fragile X Topline, And Narcolepsy Trial; Six Phase 3 Programs Expected By
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 13, 2025 by benzinga